Oracle (ORCL) completes $5 billion Series D Mandatory Convertible Preferred Stock offering closing February 5, 2026 ... Read more

FDA updates capecitabine and 5-FU labels to emphasize DPD deficiency risks... Read more

FDA updates DPD deficiency warnings for capecitabine and 5-FU to prevent life-threatening toxicities... Read more

FDA releases new informed consent template for expanded access programs... Read more

J&J recalls CEREPAK Detachable Coil Systems over detachment failure risk; four injuries, one death reported. Immediate removal advised. ... Read more

FDA updates antibacterial susceptibility testing standards, recognizing CLSI guidelines for key drugs; some drugs lack recognized standards. ... Read more

FDA updates antimicrobial susceptibility standards and recognizes new CLSI guidelines effective through 2026... Read more

Cefiderocol gains approval for complicated UTIs and pneumonia with specific pathogen susceptibility data... Read more

Recall of Abbott FreeStyle Libre 3 and Plus sensors due to incorrect glucose readings... Read more

President Trump highlights historic achievements and outlines future plans in exclusive NBC interview... Read more

FDA Advances Antimicrobial Resistance Fight with FY26 Funding and Research Initiatives... Read more

FDA advances rare disease drug development with new policies, stakeholder collaborations, and expanded orphan drug incentives... Read more

FDA launches LEADER 3D to address rare disease drug development challenges... Read more

First approvals for multiple rare diseases including thymidine kinase 2 deficiency, Barth syndrome, and Niemann-Pick Type C... Read more

FDA Advances Rare Disease Initiatives with New Programs and Upcoming Virtual Events... Read more

FDA grants pediatric exclusivity for 188 drugs since 2007, including Abacavir/DTG/lamivudine and Apixaban; updates ongoing. ... Read more

FDA releases draft guidance on patient preference studies to inform drug development and approvals... Read more

FDA updates include new draft and final guidance on efficacy studies, biosimilarity, manufacturing, and clinical trial practices through 2026. ... Read more

FDA advances tools to accelerate medical product development and improve patient access... Read more

Recall of dried Croaker Fish due to inadequate evisceration risking bacterial toxins... Read more

Rates Unchanged as Inflation Near 2% Target; Growth Resilient Despite Global Risks... Read more

FDA eases "no artificial colors" claims, approves beetroot red and spirulina extract, supporting industry shift to natural food dyes... Read more

3M (MMM) appoints Neil G. Mitchill, Jr. to its Board of Directors effective February 6, 2026, adding a financial expert to the Audit and Nominating and Governance Committees. ... Read more

Interest rates held at 2%, 2.15%, 2.40%; inflation target remains central focus amid global uncertainties. ... Read more

Bristol-Myers Squibb (BMS) reports Q4 2025 revenue of $12.5B, up 1% year-over-year, reflecting steady growth amid market challenges. ... Read more

Monetary Penalty on Daund Urban Co-operative Bank... Read more

Monetary Penalty on Agartala Co-operative Urban Bank Limited... Read more

Monetary Penalty on The Jeypore Co-operative Urban Bank Limited... Read more

Anhui to accelerate 5G, data, and infrastructure development in 2026... Read more

Jiangsu outlines strategic goals for info-communications sector during 15th Five-Year Plan... Read more